Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression.

Cureus·2026
Same author

The Feasibility of Home-Based Estimation of Circadian Timing in Veterans With Insomnia and Past Traumatic Brain Injury.

The Journal of head trauma rehabilitation·2026
Same author

Consultation-Liaison Case Conference: Stimulant-Induced Tardive Dyskinesia.

Journal of the Academy of Consultation-Liaison Psychiatry·2025
Same author

Reduced State Psychiatric Hospital Capacity and Increased Restraint Use: A Case Series From a Community Psychiatric Hospital.

Cureus·2025
Same author

Correction: Elucidating treatment targets and mediators within a confirmatory efficacy trial: study protocol for a randomized controlled trial of cognitive-behavioral therapy vs. light therapy for winter depression.

Trials·2025
Same author

Effects of repeated balneotherapy on skin hydration and psychophysiological stress: findings from a 16-week korean spa trial.

International journal of biometeorology·2025
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Related Experiment Videos

Suicidality and montelukast.

Partam Manalai1, Jong-Min Woo, Teodor T Postolache

  • 1Mood and Anxiety Program, University of Maryland School of Medicine, Department of Psychiatry, 685 West Baltimore Street, MSTF Building Room 930, Baltimore, MD 21201, USA.

Expert Opinion on Drug Safety
|June 10, 2009
PubMed
Summary
This summary is machine-generated.

This review examines the potential link between montelukast, an allergy medication, and suicidality. Current evidence is insufficient to confirm a connection, but monitoring mood changes is recommended.

Related Experiment Videos

Area of Science:

  • Psychiatry
  • Allergology
  • Pharmacology

Background:

  • Suicide is a major public health concern, with prevention reliant on identifying and mitigating risk factors.
  • Allergic conditions are linked to mood and anxiety disorders, which are known risk factors for suicidality.
  • Concerns exist regarding the potential for suicidality associated with montelukast and other leukotriene (LT) antagonists, prompting FDA warnings.

Purpose of the Study:

  • To synthesize current understanding of the relationship between allergy, suicidality, and allergy treatments, specifically LT antagonists.
  • To integrate emerging interpretations linking allergy, mood disorders, and suicide risk factors with LT antagonist use.

Main Methods:

  • Comprehensive review of existing literature on montelukast, allergy, suicide, suicidality, and associated risk factors.
  • Analysis of positions from regulatory bodies (FDA), manufacturers, and professional organizations (allergists, immunologists) regarding montelukast and suicidality.

Main Results:

  • Insufficient scientific data currently exists to establish a definitive causal link between montelukast and suicidality.
  • The review highlights ongoing concerns and the need for further investigation into the potential association.

Conclusions:

  • While a direct link between montelukast and suicidality is not proven, vigilance is necessary.
  • Routine medical practice should incorporate inquiries about mood alterations and suicidal ideation in all patients.